Navigation Links
Genetic testing for breast or ovarian cancer risk may be greatly underutilized
Date:5/21/2009

Although a test for gene mutations known to significantly increase the risk of hereditary breast or ovarian cancer has been available for more than a decade, a new study finds that few women with family histories of these cancers are even discussing genetic testing with their physicians or other health care providers. In a report in the Journal of General Internal Medicine, which has been released online, investigators from the Massachusetts General Hospital (MGH) Institute of Health Policy and Dana-Farber Cancer Institute note that their findings illustrate the challenges of bringing genetic information into real-world clinical practice.

"Testing for BRCA1 and 2 mutations has been around a long time and should be a good indicator of whether genetic testing is making its way into regular medical practice," says Douglas Levy, PhD, of the MGH Institute for Health Policy, the study's lead author. "When a well-established genetic test is not being incorporated into clinical practice when appropriate, we are a long way from meeting the promise of personalized, genetically-tailored medical care."

Most women's lifetime risk of breast cancer is about 13 percent, and the risk for ovarian cancer is less than 2 percent. But women with mutations in the BRCA1 or BRCA2 genes may be 3 to 7 times more likely to develop breast cancer and 9 to 30 times more likely to develop ovarian cancer than women with unaltered forms of the genes. Several organizations have issued clinical guidelines designating who should be screened for BRCA1/2 mutations, and while there have been discrepancies among the guidelines, all of them include a history of breast or ovarian cancer in close relatives among the criteria indicating elevated risk. The authors note that most U.S. health insurers cover at least part of the cost of BRCA1/2 testing for at-risk women.

The current study analyzed data from the 2000 and 2005 National Health Interview Surveys, both of which included supplementary questions assessing cancer control. More than 35,000 women participating in those surveys did not have a personal history of breast or ovarian cancer, and around 1 percent of them were determined to be at high risk because a mother, sister or daughter had such a tumor. Among these high-risk women, about half were aware that genetic testing was available, but only 10 percent had discussed it with a physician, less than 5 percent had been advised to have the test, and only 2 percent had done so.

"A patient's personal preferences are paramount in her decision to undergo genetic testing, but at the very minimum high-risk patients should have a discussion with their clinician." Levy explains. "Although we didn't examine factors that may impede these discussions, I believe that improvements won't come until it becomes easier and more routine to collect, update and interpret family history information, which could come through the availability of decision support tools based on electronic medical records.

"Right now we can stress that women should be aware of their family history of breast and ovarian cancer on both sides of the family communicate that information with their physicians and update it as necessary. Any woman concerned about her family history should not hesitate to raise the topic of testing with her physician," adds Levy, who is an assistant professor of Medicine at Harvard Medical School. "In addition, organizations dedicated to cancer prevention and treatment should help disseminate the guidelines which have been updated in recent years particularly to primary care physicians."


'/>"/>

Contact: Sue McGreevey
smcgreevey@partners.org
617-724-2764
Massachusetts General Hospital
Source:Eurekalert

Related biology news :

1. DNA-Prokids: Genetic identification against traffic in human beings
2. ISU researcher identifies genetic pathway responsible for much of plant growth
3. Genetic factors may predict depression in heart disease patients
4. 100 reasons to change the way we think about genetics
5. Study finds genetic links to age of first menstrual period and menopause
6. ACLU -- Myriad Genetics lawsuit will become landmark case
7. UC Riverside geneticist receives highest honor from Botanical Society of America
8. Most extensive genetic resource for reef-building coral created
9. UNC study identifies genetic cause of most common form of breast cancer
10. American College of Medical Genetics affirms importance of newborn screening dried blood spots
11. Comprehensive genetic study paves way for new blood-pressure medicines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/9/2016)... 2016 Paris Police Prefecture ... security solution to ensure the safety of people and operations ... the major tournament Teleste, an international technology group ... announced today that its video security solution will be utilised ... up public safety across the country. The system roll-out is ...
(Date:6/2/2016)... June 2, 2016 The Department of ... awarded the 44 million US Dollar project, for the ... Plates including Personalization, Enrolment, and IT Infrastructure , ... the production and implementation of Identity Management Solutions. Numerous renowned ... Decatur was selected for the most ...
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory ... technical consulting, provides a free webinar on Performing Quality Investigations: Getting ... at 12pm CT at no charge. , Incomplete investigations are still a major ...
Breaking Biology Technology: